Jump to content

Clodoveo Ferri

Edit links
From Wikipedia, the free encyclopedia
Clodoveo Ferri
Born (1947-03-22) 22 March 1947 (age 77)
Cropani, Calabria, Italy
Alma materUniversity of Pisa (1972)[1]
OccupationItalian research scientist
Scientific career
FieldsRheumatology
InstitutionsUniversity of Modena and Reggio Emilia

Clodoveo Ferri (born 22 March 1947) is an Italian researcher in the field of clinical rheumatology, immunology and internal medicine. A native of Cropani, a small town in Calabria, Italy, Clodoveo Ferri graduated cum laude from the University of Pisa and later specialized in internal medicine and rheumatology.

From January 2003 to November 2017, Clodoveo Ferri was Professor of Rheumatology, Chief of the Chair of Rheumatology and director of the Postgraduate School of Rheumatology at the University of Modena and Reggio Emilia in Modena, Italy. Following his retirement, he continued his activity as a research collaborator at the same University.[1]

Since 1972, the majority of Ferri's work is mainly devoted tof systemic sclerosis, cryoglobulinemic vasculitis (mixed cryoglobulinemia) and other autoimmune systemic disorders.

His most notable discovery regard the causative role of the hepatitis C virus (HCV) in the majority of patients with mixed cryoglobulinemia (cryoglobulinemic vasculitis) and in a significant percentage of patients with B-cell non-Hodgkin's lymphoma.[2]

Ferri is a member of the SIR (Italian Society of Rheumatology)[3] and GISC (Italian Group for the Study of Cryoglobulinemias), and an international fellow of the American College of Rheumatology.[4]

Scientific activity

[edit]

Ferri's work includes clinical and laboratory investigations of different autoimmune and neoplastic diseases; in particular, he investigated the pathogenetic role of some viruses in mixed cryoglobulinemia (cryoglobulinemic vasculitis) and systemic sclerosis (scleroderma). In 1991, soon after the discovery of the hepatitis C virus (HCV), he demonstrated the presence of serum viral genome (HCV-RNA) in a large series of mixed cryoglobulinemia patients. This finding suggested a causative role of HCV in other virus-related extrahepatic manifestations, including autoimmune and lymphoproliferative disorders. The association of HCV with B-cell non-Hodgkin’s lymphoma was first demonstrated in 1994.[5][6] On the basis of these studies, confirmed and expanded by other authors worldwide, Clodoveo Ferri suggested the term "HCV syndrome", which refers to particular autoimmune-neoplastic disease complex triggered by HCV infections in predisposed individuals.[7]

Moreover, Ferri investigated the pathogenetic role of parvovirus B19 and cytomegalovirus (CMV) in systemic sclerosis (scleroderma).

Ferri has published over 450 scientific papers in international journals, see PubMed[8] on the following topics:

1. Etiopathogenetic role of different viruses in autoimmune and neoplastic diseases:

  • 1990-91: identification of HCV as main triggering factor of mixed cryoglobulinemia (cryoglobulinemic vasculitis).[9][10] [2] [11]
  • 1994: identification of HCV as triggering factor in a significant percentage of patients with B-cell non-Hodgkin’s lymphoma.[2][5][12]
  • 1993: possible role of HCV in patients with porphyria cutanea tarda, autoimmune hepatitis, autoimmune thyroiditis, and type 2 diabetes.[13]
  • 1999: possible role of HCV in papillary thyroid cancer.[14]
  • 1999: possible role of parvovirus B19 and CMV in systemic sclerosis (scleroderma).[15] In this respect, significantly higher prevalence of parvovirus B19 infection was originally demonstrated in both bone marrow and skin of scleroderma patients compared to controls. [7]

2. Serological studies and therapeutic trials on different rheumatic disorders (rheumatoid arthritis, SLE, systemic sclerosis, mixed cryoglobulinemia)[8]

3. Etiopathogenesis, clinical features, survival, and treatment of mixed cryoglobulinemia syndrome (cryoglobulinemic vasculitis)[8]

4. Etiopathogenesis and clinical follow-up of Raynaud’s phenomenon and systemic sclerosis (scleroderma) including classification, visceral involvement (heart, lung), survival, and treatment[8]

5. Role of plasmapheretic and dietetic treatments in some rheumatic disorders (cryoglobulinemic vasculitis, SLE, scleroderma, IgA nephropathy)[8]

6. Impact of COVID19 on autoimmune systemic diseases[8][16][17]

Ferri's scientific production and related Hirsch index (H-index) can be found on Google Scholar[18] and Scopus[14]

References

[edit]
  1. ^ "Clodoveo Ferri CV" (PDF). University of Modena. Archived from the original (PDF) on 25 November 2013. Retrieved 2 March 2014.
  2. ^ a b "Hepatitis C virus: A linkage between hematology and hepatology established through major contributions by Italian research". Haematologica. 81 (3): 193–194. January 1996. PMID 8767522.
  3. ^ SIR (Italian Society of Rheumatology)
  4. ^ American College of Rheumatology (ACR)
  5. ^ a b Ferri, C. (1994). "Non-Hodgkin's lymphoma: possible role of hepatitis C virus infection". JAMA. 272 (5): 355–356. doi:10.1001/jama.1994.03520050033023. PMID 8028163.
  6. ^ Ferri, C. (1994). "Hepatitis C Virus Infection in Patients with non-Hodgkin's Lymphoma". British Journal of Haematology. 88 (2): 392–394. doi:10.1111/j.1365-2141.1994.tb05036.x. PMID 7803287. S2CID 31923239.
  7. ^ a b Current treatment of hepatitis C-associated rheumatic diseases
  8. ^ a b c d e f "Ferri C - Search Results - PubMed". PubMed. Retrieved 2024-11-13.
  9. ^ Ferri, C. (November 1990). "Alpha-interferon in the treatment of mixed cryoglobulinemia patients. Proceedings International Cancer Update. Focus on interferon alfa-2b'". European Journal of Cancer. 27 (S4). Cannes: 81–82.
  10. ^ Ferri, C. (1991). "Association between hepatitis C virus and mixed cryoglobulinemia". Clinical and Experimental Rheumatology. 9: 621–624.
  11. ^ Editorial (1996). "Hepatitis C Virus: A Linkage Between Hematology and Hepatology Established Through Major Contributions By Italian Research". Haematologica. 81 (3): 193–194. PMID 8767522. Retrieved August 26, 2020.
  12. ^ "Letter" (PDF). Archived from the original (PDF) on 2014-05-28. Retrieved August 26, 2020.
  13. ^ Ferri C, et al: HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis. 2007 Sep;39 Suppl 1:S13-21.
  14. ^ a b Antonelli A, Ferri C, Fallahi P Thyroid cancer in patients with hepatitis C infection. JAMA 1999; 281(17):1588.
  15. ^ Ferri C, et al: Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol 1999; 17(6):718-20.
  16. ^ Ferri, Clodoveo; Giuggioli, Dilia; Raimondo, Vincenzo; L'Andolina, Massimo; Tavoni, Antonio; Cecchetti, Riccardo; Guiducci, Serena; Ursini, Francesco; Caminiti, Maurizio; Varcasia, Giuseppe; Gigliotti, Pietro; Pellegrini, Roberta; Olivo, Domenico; Colaci, Michele; Murdaca, Giuseppe (2020-08-27). "COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series". Clinical Rheumatology. 39 (11): 3195–3204. doi:10.1007/s10067-020-05334-7. ISSN 1434-9949. PMC 7450255. PMID 32852623.
  17. ^ Ferri, Clodoveo; Giuggioli, Dilia; Raimondo, Vincenzo; Fallahi, Poupak; Antonelli, Alessandro; COVID-19 & ASD Italian Study Group (September 2023). "COVID-19 in Italian patients with rheumatic autoimmune systemic diseases". Annals of the Rheumatic Diseases. 82 (9): e211. doi:10.1136/annrheumdis-2020-219113. hdl:11568/1056859. ISSN 1468-2060. PMID 33055077.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  18. ^ "Clodoveo FERRI". scholar.google.com. Retrieved 2024-11-13.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Clodoveo_Ferri&oldid=1257392373"